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The explosion of high-throughput sequencing data has revealed the complexity and diversity of the transcriptome. These data have also unexpectedly revealed that only 1–2% 
of the transcriptome provides instructions for the synthesis of 
functional proteins, while the remaining 98–99% gives rise to a 
plethora of ncRNAs, including transfer RNAs (tRNAs), ribosomal 
RNAs (rRNAs), intronic RNAs, small nuclear (sn)RNAs, small 
nucleolar (sno)RNAs, microRNAs (miRNAs) and long noncoding 
RNAs (lncRNAs). A recent addition to the expanding list of regu-
latory ncRNAs is the emerging class of enhancer RNAs (eRNAs), 
which are transcribed from enhancers in a tissue-specific man-
ner. Increasing evidence that ncRNAs regulate gene expression 
has fundamentally altered how the scientific community views 
RNA-mediated gene regulation. These new advances in our under-
standing of ncRNAs have also piqued an interest in pursuing inves-
tigations of them, as the functions of the vast majority of ncRNAs 
remain to be determined.
Enhancers are classically defined as DNA sequences that regulate 
the gene expression networks underlying distinct cellular identi-
ties and cellular responses to environmental cues1–7. The ENCODE 
Consortium estimates that there are >400,000 putative enhancers 
encoded by the human genome8. Taken together, the evidence that 
enhancers account for a significant proportion of the genome and the 
identification of disease-associated genetic variants within enhancers 
underscores the importance of understanding how these elements are 
regulated and how they function in gene expression control8,9. While 
sequencing technologies have advanced the ability to predict enhancer 
location and activity, their functional dissection remains challenging 
due, in part, to their ability to act over long and variable distances 
with respect to their target genes and to the propensity of individual 
enhancers to regulate multiple genes (reviewed in ref. 10). Additional 
challenges are that enhancer activity is dynamic and restricted to par-
ticular cell types or tissues and environmental signals3–7. Moreover, the 
prediction of specific sequences that contribute to enhancer function 
is problematic because of their modest sequence conservation across 
species11–15. It may be that a common function underlies enhancer 
evolution, given that enhancer function has been shown to be con-
served without discernible sequence conservation16–18. Together, these 
studies indicate the need to continue improving methodologies that 
aid in both the functional dissection of enhancers and in uncovering 
the mechanisms directing their evolution.
Many different models for how enhancers function in gene con-
trol have been proposed since their initial discovery nearly four 
decades ago19–21. Specifically, there is considerable evidence demon-
strating that looping of distal enhancers to their target promoters is 
required for enhancer function (reviewed in ref. 22). For example, 
a key study revealed that experimental induction of chromatin 
looping between the mouse β-globin (Hbb) promoter and its asso-
ciated enhancer region results in transcriptional activation of the 
Hbb gene23. Additional analyses of the forced looping of the Hbb 
enhancer and promoter regions revealed that enhancer–promoter 
contacts affect transcription by supporting an increase in the tran-
scriptional burst fraction (number of transcribing alleles), although 
the burst size (number of transcripts produced) was unaltered24. 
The role of looping in the activation or increased rate of transcrip-
tion may be due to the binding of transcription factors, cofactors 
and the general transcription machinery to enhancers, raising the 
local abundance of the transcription machinery within the vicin-
ity of specific target genes. Enhancer looping has also been shown 
to play a role in RNA polymerase II (RNAPII)-mediated transcrip-
tional elongation. Specifically, the LIM domain–binding protein 1 
(LDB1), which establishes promoter–enhancer looping, plays a key 
role in regulating the pause release of RNAPII within the β-globin 
gene25,26. Enhancers may also regulate target genes via transcripts 
produced from the enhancer regions themselves. eRNA produc-
tion is a widespread phenomenon that has been implicated in the 
regulation of gene expression in multiple cell types in response to 
various stimuli7,27–32. The emerging prevalence of noncoding eRNAs 
makes them well positioned to dynamically remodel cellular tran-
scriptomes and adds a new layer of complexity to gene regulation. 
However, an issue that remains to be resolved is whether eRNAs 
have direct roles in gene control, as current efforts to determine 
this face the challenge of uncoupling eRNA function from the act 
of enhancer transcription. Thus, it remains necessary to develop 
tools to experimentally manipulate and model the direct functions 
of eRNAs.
Enhancers as functional noncoding RNA transcription units
Nearly a decade ago, two studies reported the intriguing finding that 
enhancer regions support transcription and give rise to noncoding 
eRNAs33,34. Since the discovery of eRNAs, there have been numerous 
reports that eRNA is synthesized in a cell-type and signal-dependent 
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Noncoding RNAs (ncRNAs) direct a remarkable number of diverse functions in development and disease through their regula-
tion of transcription, RNA processing and translation. Leading the charge in the RNA revolution is a class of ncRNAs that are 
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into enhancer transcription and eRNA function.
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manner3–7. Because eRNAs are not readily detectable in steady-state 
RNA-sequencing data, their annotation depends on sequencing 
nascent RNA using approaches that include global run-on sequenc-
ing (GRO-seq)3,5–7,27,35–40, precision run-on nuclear sequencing 
(PRO-seq)41 and cap analysis gene expression (CAGE)42,43. These 
nascent transcription assays have been instrumental in uncovering 
a wide array of ncRNAs, including long noncoding RNAs, enhancer 
RNAs, promoter upstream transcripts and upstream antisense 
RNAs. Indeed, global annotation analyses have revealed that eRNA 
transcripts account for a large proportion of initiation events in the 
transcriptome, with approximately 40,000–65,000 eRNAs expressed 
in human cells4,44. The annotation of such transcripts in Drosophila 
melanogaster45,46 and Caenorhabditis elegans47 reinforces the finding 
that eRNAs are a common feature of active enhancers in metazoans.
eRNAs are produced from active enhancers that share several 
features: (i) an open chromatin state, reflected by the presence of 
DNase hypersensitive sites (DHSs); (ii) binding of transcription 
factors and cofactors, including the histone acetyltransferase p300 
and cAMP response element–binding protein (CBP); and (iii) the 
co-occurrence of histone H3 lysine 4 monomethylation (H3K4me1) 
and histone H3 lysine 27 acetylation (H3K27ac)48–52. While these 
features have guided enhancer identification, not all active enhanc-
ers that share these features direct eRNA production53. Also, not 
all active enhancers support comparable levels of transcriptional 
activity. Higher levels of eRNA synthesis have been shown to cor-
relate with an increased ratio of histone H3 lysine 4 trimethyl-
ation (H3K4me3) to H3K4me1 and increased levels of RNAPII 
occupancy37,54,55. These findings suggest that measuring H3K4me1 
accumulation alone may underestimate the number of functional 
enhancers and that H3K4me3 may be a superior predictor of the 
level of enhancer activity. Thus, identifying additional features that 
can be used to predict enhancers will improve the identification 
of functionally active enhancers and bona fide eRNAs. In turn, 
eRNAs themselves may prove to be the most reliable predictor of 
enhancer activity.
Regulation of enhancer transcription
Enhancers and promoter regions of protein-encoding genes share 
similar properties and rules for transcription initiation. Core pro-
moter sequences, such as the TATA box, nucleosome spacing and 
the assembly of general transcription factors (TFIID/RNAPII) 
and cofactors (Mediator, p300) are observed at both enhancers and 
promoters55,56. Consistent with this, several studies have revealed 
that, similar to promoter regions, transcription at enhancers pre-
dominantly occurs in a bidirectional manner4,37,46,55,57–59. Enhancers 
and promoters have also been shown to be functionally inter-
changeable in supporting RNAPII initiation: intragenic enhancers 
behave as alternative promoters and can functionally substitute for 
promoters to drive mRNA and long noncoding RNA transcrip-
tion60. Studies in Drosophila have also revealed that bidirectionally 
transcribed enhancers behave as weak promoters and, conversely, 
that bidirectionally transcribed promoters can function as strong 
enhancers53. These findings blur the classical definitions of pro-
moters and enhancers and raise the possibility that noncoding 
transcripts generated at both regulatory regions may be functional 
(reviewed in refs. 61,62).
By comparison, there are discernible differences between the 
transcriptional elongation phases of eRNA and mRNA transcript 
production. These differences primarily reflect the well-defined 
cycles of RNAPII activity, which correlate with phosphorylation 
and dephosphorylation of the carboxyl terminal domain (CTD) of 
mammalian RNAPII63–65. The CTD domain consists of a heptam-
eric sequence (YSPTSPS) repeated 52 times that is phosphorylated 
at S2, S5, S7, T4 and Y166–68. The general model of CTD phosphory-
lation during transcription is that the CTD becomes enriched with 
S5P at the 5′ ends of coding regions, and, as RNAPII elongates a 
transcript, S2P levels increase and S5P levels decrease69–71. On the 
other hand, the elongation of enhancer transcripts is distinguished 
by low levels of the S2P form of RNAPII and minimal levels of the 
elongation-specific histone mark H3K36me3, both of which are 
enriched within gene bodies of lncRNAs and mRNAs55,72. Low lev-
els of S2P are consistent with the enrichment of the Tyr1P form of 
RNAPII that is specifically found at active enhancers and not at 
the sense strand of gene promoters73,74. The prevalence of Tyr1P 
coincides with the production of eRNAs and promoter-directed 
upstream antisense transcripts (PROMPTs), both of which are rela-
tively unstable due to exosome-mediated degradation73. Notably, 
Tyr1P is required for transcription termination control in yeast68,75 
and, more recently, has been shown to prevent transcription 
readthrough at mammalian gene ends76. However, no apparent con-
tribution of Tyr1P to the regulation of transcription readthrough is 
observed at enhancers76. Thus, Tyr1P accumulation may contribute 
to different functional consequences at promoters and enhancers. 
Further demonstrating a role for elongation in enhancer regula-
tion, the RNAPII-associated transcription elongation factor SPT6 
contributes to the recruitment of Integrator to lncRNA genes. The 
Integrator subunit INTS3 is enriched at enhancer regions that gener-
ate bidirectional eRNAs, and SPT6 depletion substantially decreases 
INTS3 recruitment and eRNA production77,78. The elongation factor 
ELL3 has also been shown to regulate occupation of enhancers by 
RNAPII79. Additional studies are needed to determine whether dis-
tinct mechanisms regulate mRNA and eRNA elongation and to fully 
understand the factors underlying the regulation of transcription 
and termination at enhancers.
classification of noncoding enhancer RNAs
A comprehensive definition of eRNAs has not yet been formulated, 
as annotated eRNAs are defined as both (i) short, bidirectional, 
non-polyadenylated, non-spliced and unstable and (ii) unidirec-
tionally transcribed, spliced, polyadenylated and stable33,80,81 (Fig. 1). 
While the majority of eRNAs are not polyadenylated or spliced, 
they tend to be capped, as shown by nuclear run-on assays followed 
by 5′ cap sequencing (5′GRO-seq) and CAGE4,7,37. Consistent with 
their low abundance and instability, eRNAs are predominantly 
localized in the nucleus and chromatin-bound fractions4,33,34,36,82,83. 
The early transcription termination of eRNAs is regulated by the 
Integrator complex in a manner that is probably dependent on 
termination-triggering polyadenylation (pA)-like signals6,37,84. In 
addition, the high turnover rate of eRNAs is mediated by the nuclear 
RNA exosome complex4,84–86. The length of eRNA transcripts is pre-
dicted to be less than 150 nucleotides, based on the identification of 
transcription termination sites within ~150 nucleotides of the tran-
scription start site of enhancer loci46,87. Notably, current predictions 
of eRNA length that stem from PRO-seq and Start-seq datasets do 
not exclude the possibility of longer eRNA transcripts46,87.
The current predictions regarding eRNA length have led to 
their classification as a distinct family of lncRNAs. Nonetheless, 
lncRNAs are distinguished from eRNAs not only by their length, 
which is >200 nucleotides, but also by their processing, which is 
consistent with their stability88–90. Importantly, however, the defini-
tions of lncRNAs and eRNAs are not mutually exclusive, and it is 
thus likely that some annotated eRNAs are actually lncRNAs and 
vice versa. This inherent complexity in classifying eRNAs is due, 
in part, to the difficulty in uncoupling specific lncRNAs from their 
associated enhancer elements33,81. For example, a recent study found 
that genomic regions defined by bidirectional transcription and 
enhancer features (termed eRNA-producing centers, or EPCs) are 
located in proximity to the transcription start sites of lncRNAs80. 
The ability of the EPCs to drive lncRNA production was shown to 
be correlated with higher enhancer activity and is in part linked to 
lncRNA maturation and the presence of evolutionarily conserved 
U1 splicing motifs80. As is the case for bidirectional promoters91, the 
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enrichment of U1 splicing sites at EPCs may prevent premature ter-
mination and permit productive elongation by RNAPII to generate 
lncRNAs. It will therefore be of interest to determine whether this 
same mechanism also applies at enhancers and whether lncRNAs 
and eRNAs establish a positive transcriptional feedback loop that 
regulates eRNA and lncRNA synthesis. It should be noted, however, 
that only a minority (3–5%) of the total EPCs are in proximity to 
lncRNAs80. Similarly, the annotated lncRNAs linc-p21 (upstream of 
Cdkn1a) and Lockd (downstream of Cdkn1b) regulate gene expres-
sion in a manner that is dependent on enhancer elements that are 
mapped to lncRNA loci rather than to the lncRNAs themselves92,93. 
In addition, reports that enhancer-associated lncRNAs function in a 
manner similar to eRNAs and, conversely, that eRNAs derived from 
super enhancers function as lncRNAs, reinforce the idea that these 
two classes of ncRNAs are not mutually exclusive94,95. These studies 
are also consistent with the notion that lncRNAs may have evolved 
from eRNAs. This suggestion is based on the presence of splicing 
and 3′ processing sequences in the vicinity of specific enhancers, 
which could promote eRNA stabilization and the evolutionary selec-
tion of new trans-acting functions96. Further analyses are needed 
to unravel the respective functions associated with particular DNA 
regions and the RNA transcripts they encode. Moreover, updates to 
our systems are needed to distinguish between eRNAs and lncRNAs 
and to resolve current investigations into the functional specializa-
tion of these classes of ncRNAs.
Functional roles of enhancer transcription and eRNAs
While eRNAs have become a hallmark of active enhancers, it 
remains to be resolved whether enhancer transcription, eRNAs 
themselves, or both, are important for enhancer activity. Studies 
have demonstrated that enhancer transcription is important for 
maintaining an open chromatin state that is readily accessible to 
transcription factors and cofactors83. Specifically, investigation of 
the formation of de novo enhancers during macrophage activation 
revealed that inhibition of transcriptional elongation at enhancers 
affects H3K4me1 and H3K4me2 deposition and is independent of 
eRNAs83. Also, transcription at intragenic enhancers, and not the 
eRNA itself, was found to interfere with and attenuate host gene 
expression during embryonic stem cell differentiation97. Similarly, a 
prior report revealed a requirement for the lncRNA Lockd in regu-
lating gene expression in a manner that is dependent on its associ-
ated enhancer elements but not the Lockd transcripts92. Moreover, 
not all active enhancers support eRNA production, suggesting that 
eRNAs are not functionally important at all enhancers53. However, 
this remains a matter of continued debate, as it is presently unclear 
whether these enhancers produce low levels of eRNAs that are not 
readily detectable with current methods53. Nevertheless, a growing 
number of studies have shown that a subset of eRNAs are required 
to support the expression of cognate target genes, and we discuss 
these various eRNA functions7,27–32 in detail below.
A variety of experimental methods continue to advance our 
understanding of eRNA function. Perturbing nuclear decay path-
ways by knocking down the core components Exosc3 and nuclear 
RNase Exosc10 of the RNA exosome results in stabilization of 
eRNAs and permits their functional assessment4,85. It is impor-
tant to note that, upon RNA exosome ablation, eRNA-expressing 
regions show an accumulation of R-loops, which is consistent with 
the involvement of the RNA exosome in resolving R-loops at active 
enhancers85. Another methodology to interrogate the functions of 
eRNAs includes CRISPR-Display, in which eRNAs are tethered to 
catalytically dead Cas9 (dCas9) for targeting to specific genomic 
loci98. Also, loss-of-function studies, such as eRNA knockdown 
analyses, could be used to target the enhancer region (deletion or 
insertion of genetic elements) or the enhancer-directed transcript 
(RNAi-mediated knockdown or incorporation of antisense oligo-
nucleotides (ASO)). However, two recent studies have revealed that 
ASO-mediated knockdown is limited by its inability to discriminate 
between RNA function and the act of transcription because incorpo-
ration of ASOs results in premature transcription termination99,100. 
Several studies have also explored eRNA functions by employing 
inhibitors of transcription elongation, such as actinomycin D and 
flavopiridol28,36,83,101. These methods used to probe the functional 
consequences of eRNAs are often paired with approaches that can 
assess where in the genome the eRNAs are functioning. Specifically, 
chromatin isolation by RNA purification (ChIRP)-seq is a power-
ful method to determine the genomic sites bound by eRNAs27,102. 
In addition, single-molecule fluorescence in  situ hybridization 
(smFISH), which provides a quantitative assessment of RNAs that 
are localized at distinct transcriptionally active regions, can be 
employed to investigate the cellular localization of eRNAs29,103.
While evidence for eRNA function is rapidly emerging, it is yet 
to be determined whether eRNAs act in cis versus in trans. Given 
that the majority of eRNAs are relatively unstable, it is not sur-
prising that they are expected to act in cis4,33,34,36,82,83. Several recent 
studies have shown that eRNAs function in cis by demonstrating 
eRNA-dependent transcriptional regulation of mRNAs produced 
from loci adjacent to the corresponding eRNA-producing enhancer 
regions7,27–29,85. Specific eRNAs have been shown to function by inter-
acting with CBP and BRD4 at the enhancers where these eRNAs are 
produced and transcriptional regulators are localized28,104. However, 
eRNAs have also been found to relocate to chromosomal regions 
distinct from those they are produced from to perform functions 
in trans29. A distal regulatory MyoD enhancer (distal regulatory 
region, or DRR) is transcribed into the DRR eRNA that medi-
ates cohesin recruitment and promotes Myogenin gene expression 
in trans to control myogenic differentiation29. Similarly, an eRNA 
synthesized adjacent to the kallikrein related peptidase 3 (KLK3) 
gene functions in trans to enhance androgen receptor–dependent 
gene expression in human prostate cancer105. In both cases, the DRR 
and KLK3 eRNAs are polyadenylated, which raises the possibility 
a  2D-eRNA
Unspliced
Non-polyadenylated
Trans
Short bidirectional Long unidirectional
Spliced
Polyadenylated
Cis
b  1D-eRNA
AAAA
Fig. 1 | Molecular features that define enhancer RNAs. Schematic diagram 
to depict the differences between annotated eRNAs56. Distinct transcripts 
synthesized at enhancers are frequently classified as bidirectional 
(2D-eRNAs) or unidirectional (1D-eRNAs). a, The majority of enhancer 
transcripts are 2D-eRNAs that are comparatively short, non-polyadenylated 
and non-spliced and function in cis4,33,34,36,82,83. b, 1D-eRNAs are longer, 
unidirectional, polyadenylated and spliced33,80,81 and can function in trans29.
NAtuRE StRuctuRAL & MoLEcuLAR BioLogy | www.nature.com/nsmb
Review ARticle NAtuRe StRuctuRAL & MoLecuLAR BioLogy
that post-transcriptional regulation of eRNAs contributes to both 
increased eRNA stability and eRNA function in trans. Alternatively, 
the aforementioned eRNAs may be lncRNAs operating in trans. 
Future studies focused on establishing direct links between eRNAs 
and gene loci will aid in determining features that dictate whether 
eRNAs function in cis or in trans.
eRNAs contribute to gene control by altering the chromatin 
environment. Several functional studies have revealed that eRNAs 
play an important role in regulating gene expression by modulat-
ing chromatin structure and function. Specifically, eRNAs direct 
chromatin accessibility at protein-coding promoters106. In addi-
tion, eRNAs function in cis to contribute to the dynamic stabiliza-
tion of enhancer–promoter looping27,36,105 and in trans to regulate 
chromatin-remodeling events that modulate transcription factor 
complex assembly and gene regulation during myogenic differen-
tiation29 (Fig. 2a). eRNAs also regulate the chromatin landscape 
through their interactions with epigenetic modifying enzymes that 
deposit (‘write’) post-translational modifications on the histone 
tails. Specifically, eRNAs have been shown to promote gene expres-
sion through their ability to augment histone acetylation at enhanc-
ers through interactions with the histone acetyltransferase CBP104 
(Fig. 2b). Future analyses are required to extend the understanding 
of eRNAs in the regulation of chromatin structure and function.
eRNAs interact with transcriptional regulators to control gene 
expression. To advance our understanding of how eRNAs control 
gene regulation, numerous studies have focused on the identifi-
cation and classification of the eRNA-interacting proteome. The 
methods most frequently employed to identify direct binding part-
ners and physiological associations of eRNAs include RNA elec-
trophoretic mobility shift assays and RNA immunoprecipitation 
(UV-RIP), respectively. Purification of target eRNAs complexed 
with proteins is often performed by using biotinylated antisense 
oligonucleotide to capture the RNAs, coupled with mass spectrom-
etry (RAP-MS). These assays have identified eRNAs that regulate 
gene expression via interactions with RNAPII, various transcription 
factors and cofactors. eRNAs have been shown to interact with Yin 
Yang 1 (YY1) to increase recruitment of this transcriptional regula-
tor at enhancers107 (Fig. 3a, left). Similarly, eRNAs increase RNAPII 
occupancy at protein-coding loci28,106. It remains to be determined 
whether transcription factor and cofactor trapping at enhancers 
and gene loci is a widespread mechanism underlying eRNA func-
tion. In addition to regulating RNAPII binding, eRNAs also regu-
late RNA Pol II pause release by acting as a decoy for the negative 
elongation factor (NELF) complex30 and through activation of the 
positive transcription elongation factor b (P-TEFb) complex108  
(Fig. 3b). Several recent studies have also linked eRNA functions 
to their interactions with several general cofactors, including cohe-
sin27,36, Mediator31, CBP104 and BRD4 (ref. 28). eRNA interactions 
with cohesin and CBP augment enhancer activation through the 
regulation of chromatin looping and increased deposition of his-
tone acetylation, respectively27,36,104. eRNAs directly interact with 
BRD4 through its bromodomains (BDs) to promote greater bind-
ing of BRD4 to acetylated histones, which, in turn, contributes to 
the maintaining enhancers in an active state28 (Fig. 3a, right). Lastly, 
eRNA interactions with Mediator are required to support transcrip-
tional activation by promoting chromatin looping31. Importantly, 
all of these studies are consistent with eRNAs exhibiting their 
functional roles in collaboration with different binding partners 
involved in transcriptional regulation.
eRNAs in tumor-promoting gene regulation and genomic insta-
bility in cancer. Since enhancers are known to control the selec-
tion and maintenance of hundreds of cell types, it is not surprising 
that enhancer misregulation has emerged as a driving force behind 
many types of human cancers. eRNAs are expressed across human 
cancer tissues3,5,21,27,31, supporting their potential relevance as thera-
peutic targets and biomarkers. The biggest barrier to moving these 
molecules to the clinic as a new generation of actionable targets is 
the lack of knowledge of their biological functions. However, recent 
studies have begun to uncover roles for eRNAs in the regulation 
of tumor-promoting gene expression programs. The ARIEL eRNA 
has recently been shown to promote activation of an oncogenic 
gene-expression program in T-cell acute lymphoblastic leukemia109. 
eRNAs have also been shown to regulate the chromatin interactions 
and transcriptional activities of BRD4, a potent cancer dissemina-
tor, that are required to regulate a subset of tumor-promoting genes 
in response to chronic TNF-α signaling in colon cancer28 (Fig. 3).
Beyond their roles in the regulation of gene expression in can-
cer, eRNAs are also linked to the maintenance of genome stability. 
Increased levels of eRNAs in human cancers have been shown to 
promote the formation of three-stranded nucleic acid DNA:RNA 
hybrids (R-loops) that interfere with DNA replication and, in 
turn, induce chromosome rearrangements and genome instabil-
ity (reviewed in ref. 110). Consistent with the possibility that aber-
rant eRNA synthesis contributes to tumorigenesis is the finding 
that enhancer transcription leads to activation-induced cytidine 
deaminase (AID) mistargeting, which promotes genome insta-
bility and malignancy111. Similarly, oncogenes, including mutant 
p53, have been shown to drive potent levels of eRNA synthesis in 
human colon cancer cell lines3, which may lead to aberrant R-loop 
formation and the loss of genome stability. Future studies that 
examine the mechanisms underlying the accumulation of eRNAs, 
R-loop formation and gene expression changes, and the con-
nections between these events in normal versus cancer cells, will 
help to address remaining questions in the enhancer biology field. 
One unresolved issue relates to how enhancer regions are able to 
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Fig. 2 | eRNA regulation of enhancer–promoter interactions and the 
epigenetic state of chromatin. a, Schematic diagram depicting the roles 
of eRNAs acting in cis to regulate specific enhancer–promoter looping 
by supporting cohesin binding at enhancers27,106 (left) and influencing 
chromatin accessibility by modulating cohesin complex recruitment 
in trans to regulate gene expression (right). b, Schematic showing that 
eRNAs stimulate the catalytic activity of the histone acetyltransferase 
CBP to regulate increased deposition of histone acetylation, which in turn 
contributes to greater enhancer activation104.
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support high levels of eRNA synthesis while remaining uninhibited 
by increased formation of R-loops. Another possibility that remains 
to be explored is whether single nucleotide polymorphisms (SNPs) 
that are localized within enhancers alter or disrupt eRNA functions; 
a recent high-throughput analysis that identified SNPs that alter 
the regulatory functions of enhancers and promoters is consistent 
with this possibility9. Genes that exhibit transcriptional burst fre-
quency differences were found to have higher densities of SNPs in 
their enhancer but not promoter regions. Identification of enhancer 
transcription ‘signatures’ and elucidation of the mechanisms 
underlying the precise functions of eRNAs in cancers will pave 
the way for the potential use of eRNAs as diagnostic markers and 
therapeutic targets.
Mechanisms underlying the functions of eRNAs
Recent studies have demonstrated that eRNA functions are 
largely mediated through interactions with eRNA binding part-
ners27,28,31,36,104,105. Several studies suggest that RNA sequence is prob-
ably not involved in contributing to the specificity of eRNA–protein 
interactions. For example, both CBP104 and BRD428 were found to 
bind a broad spectrum of RNAs, which is consistent with these fac-
tors binding RNA in a non-sequence-specific manner. However, 
both of these studies suggest that the specificity of these eRNA 
interactions stems from eRNAs interacting with CBP and BRD4 in 
an enhancer-specific manner28,104. This property may be exploited 
by the pervasive binding of transcriptional cofactors throughout the 
genome, such that RNAs could stimulate activity locally, indepen-
dently of RNA sequence. Nonetheless, only a few specific eRNAs 
were examined for direct interactions with CBP104 and BRD428, sug-
gesting that additional analyses are needed to investigate the speci-
ficity of interactions between eRNAs and their respective binding 
partners. Consistent with the possibility that eRNAs may function 
through specific sequence motifs is the finding that a similar motif 
is present in a subset of androgen-receptor-regulated eRNAs that 
promotes transcription by activating P-TEFb108. In addition, cur-
rent analyses cannot rule out the contributions of eRNA length, 
structure, and conformational flexibility. A further possibility that 
remains to be explored is whether post-translational modifica-
tion of eRNAs contributes to the regulation and function of eRNA 
binding partners. To this end, deposition of 5-methylcytosine on 
eRNAs supports the coactivator functions of PGC1-α during meta-
bolic stress112. Chemical modification of eRNAs may thus provide 
an additional layer of regulation in the interactions between eRNAs 
and binding partners and may thereby have important implications 
for enhancer and gene control.
Interestingly, eRNAs were shown to interact with binding partners 
through noncanonical RNA binding regions (RBRs), which are dis-
tinct from the well-characterized RNA-interacting domains, includ-
ing the RNA-recognition motif (RRM)113, the hnRNPK-homology 
domain (KH)114 and the double-stranded RNA binding domain 
(dsRBD)115. For example, eRNAs have recently been shown to 
interact with the highly conserved acetyl-lysine-binding BDs of the 
BET family members and the single BDs of the non-BET proteins 
BRG1 and BRD728. This study raises the interesting questions of 
how prevalent eRNA interactions with chromatin reader domains 
are and what the significance of such interactions is in the regula-
tion of chromatin and in gene control. Several RBRs in CBP/p300 
were predicted to interact with eRNAs104; however, this was attrib-
uted to a single CBP RBR that resides within the catalytic histone 
acetyltransferase domain. eRNA interactions with this domain were 
shown to contribute to the displacement of the CBP activation loop 
that blocks substrate binding to the active site to allow for enhanced 
histone acetyltransferase activity104. Moreover, further analyses will 
be needed to investigate the significance of eRNA interactions with 
(i) both canonical and noncanonical RNA binding regions; (ii) mul-
tiple domains within a single protein, as was predicted for CBP104; 
and (iii) multiple subunits within a multiprotein complex. Taken 
together, these studies allude to the exciting possibilities for advanc-
ing our mechanistic understanding of the biological and biochemi-
cal roles of eRNAs and their corresponding binding partners. Yet 
additional studies are required to obtain a comprehensive list of 
eRNA binding partners and to uncover the molecular mechanisms 
underlying these interactions. Such analyses are likely to have broad 
implications, based on widespread eRNA synthesis in different cell 
types and because a large-scale analysis of eRNA binding partners 
has not yet been performed.
Future perspectives
The widespread involvement of ncRNAs in the regulation of gene 
expression suggests that a great deal remains to be discovered about 
the functional significance of these important molecules. On the 
basis of current studies, the causal roles of eRNAs are likely to be 
important for the regulation of a subset of enhancers and target loci. 
Nonetheless, additional evidence is required to definitively iden-
tify eRNAs and to elucidate their biological roles. Notably, these 
advances will require improvements to methodologies that cannot 
currently distinguish between the roles of enhancer transcription 
and eRNAs. As such, approaches that evaluate enhancer-mediated 
transcription dynamics and the direct roles of eRNAs are needed 
to advance our understanding of enhancer regulation and function. 
This includes cell-free systems, which could be used to manipulate 
and model the roles of eRNAs and eRNA-associating binding pro-
teins and thus close an important gap in our knowledge of enhancer 
and gene regulation.
a  TF and chromatin reader trapping
b  Transition of RNAPII into productive elongation
Enhancer
Acetylation
Acetylation
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eRNA
RNA Pol II
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eRNA
RNA Pol II
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P
Fig. 3 | eRNAs modulate the chromatin interactions of transcriptional 
regulators. Schematic illustrating the role of eRNAs in directly regulating 
transcription. a, eRNAs regulate the enhancer occupancy of the 
transcription factor YY1107 and the transcriptional coactivator BRD4 (ref. 28). 
b, eRNAs promote RNAPII chromatin engagement and the transition from 
RNAPII pause release to productive elongation by acting as a decoy for 
NELF30 and by contributing to the activation of P-TEFb108.
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Future directions will also involve cataloging additional eRNAs, 
determining their cellular localization and expression patterns and 
exploring their mechanisms of action. Toward this goal, it will be 
necessary to define a more comprehensive list of eRNA binding 
partners and to determine the regulatory parameters underlying 
their interactions with eRNAs. Categorical data analyses and sort-
ing of eRNA binding partners into functional and structural classes 
will provide new insights into how eRNAs interact with eRNA bind-
ing partners. These analyses could also provide new insights into 
whether eRNA binding partners display specificity for different 
RNA sequences and structural features and, if so, whether either 
or both of these possibilities impart the eRNA–protein complexes 
with varying functions. It will also be important to address the 
question of whether the activity of eRNAs and their corresponding 
eRNA binding partners is tailored to specific enhancers to con-
trol distinct gene expression programs and cellular processes. 
It will also be important to consider the recently identified role 
of eRNA-containing protein complexes in the regulation and func-
tion of the RNA-dependent architecture that directs the formation 
and integrity of phase-separated condensates116 (Fig. 4). Several 
questions that remain to be addressed include the following: how do 
eRNAs contribute to changes in the physical properties of conden-
sates, and can eRNAs specifically regulate the sorting of proteins and 
regulatory DNA elements into specific condensates? Which eRNA 
motifs are sufficient for the formation of phase separated particles? 
Finally, it remains to be determined whether eRNA sequences that 
show increased affinity for binding partners exist. High-affinity 
binding sites and the potential for cooperative spreading of bind-
ing partners on eRNAs, which has been shown for mRNAs, could 
play an important role in facilitating multivalent interactions, which 
contribute to phase separation117. In addition, eRNAs provide the 
potential for multivalency in RNA-mediated chromatin associa-
tions28, as demonstrated by the recent finding that eRNAs interact 
with BDs to facilitate enhanced chromatin associations and the 
downstream transcription-associated functions of BRD4. Histone 
reader proteins tend to form weak interactions with chromatin 
through their recognition of and direct interactions with particu-
lar histone marks. This model would be consistent with previous 
findings that the overall affinity and specificity of chromatin bind-
ing is enhanced when multiple chromatin-interacting domains in a 
single protein or within a multiprotein complex are able to engage 
with chromatin118.
In summary, an explosion of studies in the last decade has identi-
fied noncoding enhancer transcripts that are produced from a wide 
array of active enhancers in multiple cell types and tissues. Building 
on this foundation, the next decade will be an exciting time for 
uncovering the mechanisms that control enhancer transcription 
and eRNA functions in gene regulation and biological processes. 
Progress toward this goal will be the next fundamental step in 
advancing our understanding of gene regulation.
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